A deep eutectic solvent is an effective cryoprotective agent for platelets.

Me2SO cryopreservation deep eutectic solvent dimethyl sulfoxide platelet transfusion

Journal

Cryobiology
ISSN: 1090-2392
Titre abrégé: Cryobiology
Pays: Netherlands
ID NLM: 0006252

Informations de publication

Date de publication:
28 May 2024
Historique:
received: 01 03 2024
revised: 09 05 2024
accepted: 27 05 2024
medline: 31 5 2024
pubmed: 31 5 2024
entrez: 30 5 2024
Statut: aheadofprint

Résumé

The most widely used method of platelet cryopreservation requires the addition of dimethyl sulfoxide (DMSO; Me2SO) as a cryoprotective agent (CPA) and pre-freeze removal of Me2SO before freezing to mitigate toxicity. However, alternative CPAs such as deep eutectic solvents (DES), which are less toxic could simplify this process. The aim of this study was to determine the effectiveness of a Proline-Glycerol (Prol-Gly 1:3) DES as a platelet CPA. Platelets were cryopreserved at -80°C using 10% Prol-Gly 1:3 (DES; n=6), or in the absence of a cryoprotectant (no CPA; n=6). Platelets were also cryopreserved according to the gold-standard blood-banking method using 5.5% Me2SO (n=6), with centrifugation and pre-freeze removal of the excess Me2SO. Platelet quality was assessed by flow cytometry and thromboelastography (TEG). Post-thaw recovery was similar between the three groups. The abundance of labile platelet glycoproteins GPIbα and GPVI were highest in the DES group, however, markers of activation (CD62P and annexin-V) were also higher in this group. In terms of function, the strength of the clot (maximum amplitude; TEG) and extent of clot retraction was better with DES platelets compared to no CPA, but lower than Me2SO platelets. DES provides a cryoprotective advantage to platelets when compared to no CPA. Importantly, when compared to Me2SO platelets, most quality parameters were similar in DES platelets. The major advantage with using a DES is biocompatibility, therefore it does not need to be removed prior to transfusion. This greatly simplifies the freezing and thawing process, avoiding the toxic effects of Me2SO.

Identifiants

pubmed: 38815783
pii: S0011-2240(24)00068-3
doi: 10.1016/j.cryobiol.2024.104913
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104913

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest: The authors have no conflicts of interest to disclose.

Auteurs

Lacey Johnson (L)

Research and Development, Australian Red Cross Lifeblood, Alexandria, NSW, Australia. Electronic address: ljohnson@redcrossblood.org.au.

Saffron J Bryant (SJ)

School of Science, College of STEM, RMIT University, Melbourne, Australia.

Pearl Lei (P)

Research and Development, Australian Red Cross Lifeblood, Alexandria, NSW, Australia.

Christopher Roan (C)

Research and Development, Australian Red Cross Lifeblood, Alexandria, NSW, Australia.

Denese C Marks (DC)

Research and Development, Australian Red Cross Lifeblood, Alexandria, NSW, Australia; Sydney Medical School, The University of Sydney, Camperdown, NSW, Australia.

Gary Bryant (G)

School of Science, College of STEM, RMIT University, Melbourne, Australia.

Classifications MeSH